Logo Image
News
Media
All VideosMedical World NewsPodcastsWeekly RecapCure ConnectionsInsightsSpecial ReportNeurologyLive Peer ExchangeMedcastPeers & PerspectivesRoundtable DiscussionsShortsShows & Podcasts
Conferences
Conference CoverageConference Listing
CME/CE
More
Partners
Publications
NeurologyLiveBridging the GapsInternational Journal of MS Care
Resources
Expert AuthorsFDA NewsFeaturesFuture Leaders in NeurologyGiants of Multiple SclerosisInteractive ToolsJob BoardLive EventsNeurology ResourcesParkinsonism Practical GuideSponsoredThe G.L.O.B.Virtual Events

Subscribe

  • News
  • Media
  • Conferences
  • CME/CE
  • Partners
  • Publications
  • Resources
  • Subscribe
  • Dementia and Alzheimer Disease
  • Epilepsy
  • Genetic Disorders
  • Headache and Migraine
    • Migraine
  • MS and Demyelinating Disorders
    • NMOSD
    • Multiple Sclerosis
  • Movement Disorders
    • Parkinson Disease
    • Dyskinesia
    • Huntington Disease
  • Neuro-Oncology
  • Neuromuscular
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Muscular Dystrophy
    • Ataxia
  • Rare Diseases
  • Sleep Disorders
    • Narcolepsy
    • Excessive Daytime Sleepiness
    • Insomnia
  • Stroke
Spotlight -
Expert Authors|
FDA News|
Upcoming Live Events|
CMSC 2026|
ATMRD 2026|
AAIC 2026|
Parkinsonism Practical Guide
Advertisement

Scott Newsome, DO, MSCS, FAAN

Advertisement

Articles by Scott Newsome, DO, MSCS, FAAN

Use of MRI in Diagnosing Multiple Sclerosis

ByFred Lublin, MD,Patricia K. Coyle, MD,Scott Newsome, DO, MSCS, FAAN,Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC
December 23rd 2020

2017 Changes to the McDonald Criteria: Diagnosing Multiple Sclerosis

ByFred Lublin, MD,Patricia K. Coyle, MD,Scott Newsome, DO, MSCS, FAAN,Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC
December 16th 2020
  • Prev
  • 1
  • 2
  • 3
  • Prev
Advertisement


Advertisement
Advertisement

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

1

FDA Approves Tau PET Tracer MK-6240 for Alzheimer Diagnostic Workup

2

FDA Clears Phase 2 Trial for Demyelinating Agent Lucid-MS in Progressive Multiple Sclerosis

3

CN045 Promotes Oligodendrocyte Maturation, Modest Remyelination in Preclinical MS Study

4

Ractigen Completes Phase 2 Enrollment for RAG-17 in SOD1-ALS

5

Ractigen Completes Enrollment for RAG-17 in SOD1-ALS, Tanruprubart Shows Rapid Responses in GBS, Building a Multidisciplinary SMA Clinic

  • About Us
  • Advisory Board
  • Editorial
  • Contact Us
  • Advertise
  • Contact MJH LS
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
  • Patient Care Online
HCP Live Network
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us